What Magnolia Medical Technologies does

Magnolia Medical Technologies is a Seattle-based medical device company that develops and commercializes the Steripath family of Initial Specimen Diversion Devices (ISDDs), single-use products designed to prevent contaminants from entering blood culture bottles and thereby reduce false-positive sepsis diagnoses. The core mechanism diverts the initial 0.5-2.0 mL of blood (depending on configuration) into a sealed chamber via a push-button or syringe-driven pathway before the culture sample is collected, leaving only a sterile pathway for the diagnostic specimen. The flagship Steripath ISDD and the lower-volume Steripath Micro are both FDA 510(k)-cleared with a specific indication to reduce blood culture contamination, and the company supports deployments with a complementary data and analytics service, Magnolia Analytics, that tracks contamination rates and clinical-economic outcomes for hospital customers.

The company sells primarily to U.S. acute care hospitals, academic medical centers, and integrated delivery networks, targeting infection preventionists, nursing and phlebotomy staff, laboratory leaders, and hospital administration. Its go-to-market combines a dedicated U.S. enterprise sales force with a co-exclusive commercial partnership with BD (Becton, Dickinson and Company) for co-selling and co-marketing, supplemented by endorsed group purchasing organization agreements with Vizient, Premier, Ascension, Healthtrust, Cardinal Health, and others, plus a Federal Supply Contract with the U.S. Department of Veterans Affairs. Pricing is not publicly disclosed and is quote-based at the hospital-system level; Magnolia offers a Clinical Performance Guarantee of at least 50% contamination reduction or money back, and backs its claims with more than 20 peer-reviewed clinical studies documenting 83-88% contamination-rate reductions and near-elimination of false-positive CLABSIs across hundreds of U.S. hospital customers.

The business model is a consumable, per-procedure hardware sale of disposable ISDD devices, with recurring-style analytics support layered on top. Revenue is generated through direct purchasing relationships with healthcare facilities and channel partners, and the addressable problem is large: roughly 40% of positive blood cultures are estimated to be false positives due to contamination, contributing to approximately $6 billion in unnecessary U.S. healthcare spending annually. Magnolia has raised approximately $117 million across equity and debt financing since founding, is backed by RTW Investments, Sectoral Asset Management, HealthQuest Capital, Evidity Health Capital, SightLine Partners, and others, and operates with an intellectual property portfolio exceeding 200 issued patents and 50+ pending applications that has been successfully enforced against the closest direct competitor, Kurin, Inc.

Name

Magnolia Medical Technologies

Legal name

Magnolia Medical Technologies, Inc.

Website

https://magnolia-medical.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

101–250 employees

Short description

Magnolia Medical Technologies develops and sells the Steripath Initial Specimen Diversion Device, an FDA 510(k)-cleared disposable medical device that reduces blood culture contamination and false-positive sepsis diagnoses, serving U.S. hospitals and healthcare systems through direct enterprise sales, a BD co-exclusive partnership, and GPO contracts.

Ownership category

akta.pro rank

Product category

Diagnostic Medical Devices

NAICS

Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)

Keywords

• Blood culture devices
• Diagnostic medical devices
• Specimen diversion technology
• Sepsis testing solutions
• Contamination prevention devices

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

1. Medical Device Sales: Sale of Steripath and Steripath Micro Initial Specimen Diversion Device disposable products to hospitals and healthcare systems. Products are single-use medical devices used during blood culture collection procedures. Revenue generated through direct purchasing relationships with healthcare facilities.
2. Clinical Analytics Services: Magnolia Analytics service providing data capture and analytics to help hospitals quantify clinical and cost effectiveness of preventing sepsis misdiagnosis.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Core offering

Magnolia Medical Technologies develops and manufactures the Steripath Initial Specimen Diversion Device (ISDD) platform, a family of FDA 510(k)-cleared single-use medical devices that divert the initial 0.5–2.0 mL of blood to prevent contaminants from entering blood culture bottles, reducing false-positive sepsis test results. The company also offers Magnolia Analytics, a data service that helps hospitals track contamination rates and quantify clinical and economic outcomes.

Product overview

Magnolia Medical Technologies offers the Steripath platform—a family of medical devices designed to reduce blood culture contamination during sepsis testing. The core offering includes the Steripath Initial Specimen Diversion Device (ISDD) and Steripath Micro, which divert the initial blood specimen to prevent contaminants from entering culture bottles. These devices are complemented by Magnolia Analytics, a data service for tracking clinical and cost outcomes. The company also runs the Mission to ZERO initiative to promote adoption of contamination-prevention practices. All Steripath devices are FDA 510(k)-cleared and backed by extensive clinical evidence from peer-reviewed studies.

Differentiator

Problem solved

Functional benefit

Brands

• Steripath: Initial Specimen Diversion Device platform for reducing blood culture contamination and sepsis misdiagnosis
• Steripath Micro
• Magnolia Analytics
• Mission to ZERO

Products and services

• Steripath Initial Specimen Diversion Device (ISDD) The flagship blood culture collection device that diverts and sequesters the initial 1.5 to 2.0 mL of blood prior to specimen collection to reduce contamination. FDA 510(k)-cleared with specific indication to reduce blood culture contamination for sepsis testing accuracy. Sold to hospitals and healthcare systems.
• Steripath Micro A low-volume Initial Specimen Diversion Device (ISDD) designed for vulnerable patient populations that diverts the initial 0.5 to 1.0 mL of blood into a diversion chamber to prevent contamination, then opens a sterile pathway for blood culture collection. FDA 510(k)-cleared with specific indication to reduce blood culture contamination. Features push-button collection and integrates with BD Vacutainer UltraTouch push-button blood collection sets.
• Magnolia Analytics A data analytics service that streamlines data capture and quantifies the clinical and cost effectiveness of preventing sepsis misdiagnosis, helping hospitals track contamination rates and outcomes. Sold to hospitals and healthcare systems.

Quantifiable outcome

• 83-88% reduction in blood culture contamination rates for peripheral venipuncture
• +8 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature3 records

Partnerships

Eight partnerships are on record, tiered core and major.

• BD (Becton, Dickinson and Company)coreStrategic or Co-development Partner · 1 October 2022Co-exclusive commercial collaboration announced October 2022 for co-selling and co-marketing Steripath and Steripath Micro ISDD platforms. Both companies leverage their sales forces to drive adoption across U.S. hospitals. Steripath Micro integrates BD Vacutainer UltraTouch push-button blood collection sets.
• MHA SolutionsmajorChannel Partner/ Reseller/ Distributor · 1 December 2021Exclusive endorsed agreement for Steripath ISDD products through MHA Solutions' distribution network serving healthcare providers.
• Healthcare Providers Insurance CompanymajorChannel Partner/ Reseller/ Distributor · 1 December 2021Exclusive endorsed agreement for Steripath ISDD products, providing insurance company members access to the technology.
• VizientmajorChannel Partner/ Reseller/ DistributorGPO member and award recipient. Vizient represents 101 academic medical centers and healthcare organizations.
• Premier Inc.majorChannel Partner/ Reseller/ DistributorGroup purchasing organization partnership providing access to Premier's network of healthcare providers.
• AscensionmajorChannel Partner/ Reseller/ DistributorIntegrated delivery network partnership for Steripath products across Ascension healthcare facilities.
• Cardinal HealthmajorChannel Partner/ Reseller/ DistributorDistribution partner providing access to Cardinal Health's healthcare supply chain network.
• ROI HealthtrustmajorChannel Partner/ Reseller/ DistributorGPO partnership providing member hospitals access to Steripath products.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Kurin, Inc. Kurin is the most direct competitor to Magnolia's Steripath — it also manufactures Initial Specimen Diversion Devices (Kurin Lock) designed to reduce blood culture contamination. The two companies have engaged in multiple rounds of patent litigation, confirming direct competition in the ISDD category.
• Greiner Bio-One: Greiner Bio-One manufactures Vacuette blood collection tubes and devices used in clinical phlebotomy. It is a relevant comparable for hospitals evaluating specimen collection devices alongside Steripath.
• Sarstedt: Sarstedt produces S-Monovette and other blood/specimen collection devices used in hospital and laboratory phlebotomy. It competes for the same hospital blood collection workflows that Magnolia's Steripath addresses.

Broad incumbents

• Becton, Dickinson and Company (BD): BD is the global incumbent in blood collection (Vacutainer) and blood culture systems (BACTEC). BD is simultaneously Magnolia's co-exclusive commercial partner and a competitor, making it the most strategically intertwined peer in the specimen collection category.
• bioMérieux: bioMérieux manufactures the BACT/ALERT blood culture incubation and detection systems, which integrate downstream from Magnolia's Steripath devices. As the dominant automated blood culture platform, bioMérieux shapes the workflow context in which Steripath is used.
• ICU Medical: ICU Medical manufactures IV therapy, closed blood sampling, and blood collection/spike products for hospitals. Its closed blood sampling systems overlap with Magnolia's specimen collection workflow.

Emerging players

• Velano Vascular: Velano Vascular developed PIVO, a needle-free blood draw device that addresses a related pain point (repeated venipuncture for blood collection). It targets the same clinical workflow of inpatient blood collection as Magnolia.
• Tasso, Inc. Tasso manufactures OnDemand, a virtually painless capillary blood collection device. While primarily focused on decentralized/at-home sampling, Tasso intersects with Magnolia's mission to improve diagnostic specimen quality.
• Seventh Sense Biosystems: Seventh Sense developed the TAP device for push-button capillary blood collection. It is an emerging player in the broader diagnostic specimen collection space adjacent to Magnolia's hospital-focused venous specimen diversion.

Others

• Cardinal Health: Cardinal Health is a major medical product distributor and a Magnolia channel partner (exclusive endorsed Steripath agreement). It is adjacent infrastructure rather than a direct product competitor but is highly relevant to Steripath's commercial reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCPcZSuheMZuiP9-J3gRKAWA
• LinkedInlinkedin.com/company/magnolia-medical-technologies
• Xx.com/steripath
• Facebookfacebook.com/magnolia-medical-technologies-inc-209462206204008

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles21 records

Funding overview

Funding rounds9 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Magnolia Medical Technologies